Stock BMRN BIOMARIN PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
81.45 USD +0.59% Intraday chart for BioMarin Pharmaceutical Inc. -1.07% -15.53%
Jul. 01 BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 3000E Growth Index CI
Jul. 01 BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to Russell 1000 Defensive Index CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children s Bone Health
AQ
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
PR
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress
PR
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT 1:00pm ET, in Las Vegas, NV
AQ
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
PR
New Data for BioMarin's VOXZOGO for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society Annual Meeting
AQ
BioMarin: Q1 Earnings Snapshot
AQ
BioMarin Reports Record Financial Results for the First Quarter 2024
PR
BioMarin Pharmaceutical : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K
PU
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
PR
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
AQ
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
PR
BioMarin Scheduled to Participate in March Investor Conferences
AQ
BioMarin Scheduled to Participate in March Investor Conferences
PR
BioMarin: Q4 Earnings Snapshot
AQ
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
PR
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
PR
BioMarin to Present ROCTAVIAN Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders Congress
AQ
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
PR
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT 1:30 pm ET, in San Francisco, CA
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMRN Stock
  4. News BioMarin Pharmaceutical Inc.
  5. Press Releases